Literature DB >> 12553560

A mathematical model for pattern of change in beta-cell reserve and factors affecting residual reserve within the first 2 years of type 1 diabetes.

Y Altuntas1.   

Abstract

The aim of this study was to investigate the effects of age, duration of diabetes, sex and ICA (Islet cell cytoplasmic antibody) on beta-cell reserves and to develop a model within the first 2 years of Type 1 diabetes. Beta-cell reserve is evaluated as fasting (FCp) and 1 mg i.v. glucagon stimulated C-peptide (SCp) levels in 58 Type 1 diabetics and in 12 normoglycemic subjects. Patients were divided into 3 groups according to duration of diabetes: Group I (2.5+/-0.3 weeks), Group II (13.4+/-1.2 months) and Group III (24.2+/-1.8 months). FCp/SCp level in nmol/l (mean+/-SE) were as follows. Group I: 0.21+/-0.02/0.38+/-0.04, Group II: 0.15+/-0.01/0.27+/-0.02, Group III: 0.07+/-0.01/0.11+/-0.02, CONTROL GROUP: 0.42+/-0.09/1.29+/-0.13. The scatter plots of C-peptide levels vs time in all the diabetic patients fitted in to a 4th-order polynomial regression (R: 0.96-0.98). Age was strongly correlated with FCp (rs: 0.46, p<0.05) and ICA positivity affected Cp-levels negatively (p>0.05). In conclusion, as the duration of diabetes increases, response time to glucagon prolongs and amplitude of it shortens. Duration of diabetes of less than 2 weeks, feminity, puberty and ICA positivity affect beta-cell reserve negatively, conversely, masculinity, post-puberty, older age and ICA negativity affect the reserve positively. The dynamics of C-peptide response to glucagon follow a mathematical model and Type 1 diabetes causes a decrease not only in the amplitude of the response but also in the duration of the response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12553560     DOI: 10.1007/BF03344073

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

Review 1.  Beta-cell adaptation and decompensation during the progression of diabetes.

Authors:  G C Weir; D R Laybutt; H Kaneto; S Bonner-Weir; A Sharma
Journal:  Diabetes       Date:  2001-02       Impact factor: 9.461

Review 2.  Beta-cell activity and destruction in type 1 diabetes.

Authors:  F A Karlsson; C Berne; E Björk; M Kullin; Z Li; J Y Ma; A Schölin; L Zhao
Journal:  Ups J Med Sci       Date:  2000       Impact factor: 2.384

Review 3.  Aspects of the etiology, prediction, and prevention of insulin-dependent diabetes mellitus in childhood.

Authors:  M A Sperling
Journal:  Pediatr Clin North Am       Date:  1997-04       Impact factor: 3.278

4.  Autoantibodies in relation to residual insulin secretion in children with IDDM.

Authors:  J Ludvigsson; S Hellström
Journal:  Diabetes Res Clin Pract       Date:  1997-03       Impact factor: 5.602

5.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

Review 6.  Diabetes mellitus. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1985

7.  Sexual dimorphism in insulin sensitivity in adolescents with insulin-dependent diabetes mellitus.

Authors:  S A Arslanian; B V Heil; D J Becker; A L Drash
Journal:  J Clin Endocrinol Metab       Date:  1991-04       Impact factor: 5.958

8.  A high linear growth is associated with an increased risk of childhood diabetes mellitus.

Authors:  L Blom; L A Persson; G Dahlquist
Journal:  Diabetologia       Date:  1992-06       Impact factor: 10.122

9.  Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus.

Authors:  R Bonfanti; E Bazzigaluppi; G Calori; M C Riva; M Viscardi; E Bognetti; F Meschi; E Bosi; G Chiumello; E Bonifacio
Journal:  Diabet Med       Date:  1998-10       Impact factor: 4.359

10.  Natural course of remission in IDDM during 1st yr after diagnosis.

Authors:  S Martin; B Pawlowski; B Greulich; A G Ziegler; T Mandrup-Poulsen; J Mahon
Journal:  Diabetes Care       Date:  1992-01       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.